Clinical and Patient-Centered Outcomes After Minimally Invasive Non-Surgical or Surgical Approaches for the Treatment of Intrabony Defects: A Randomized Clinical Trial

2011 ◽  
Vol 82 (9) ◽  
pp. 1256-1266 ◽  
Author(s):  
Fernanda V. Ribeiro ◽  
Renato C.V. Casarin ◽  
Maria A.G. Palma ◽  
Francisco H.N. Júnior ◽  
Enilson A. Sallum ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Minimally Invasive ◽  
Randomized Clinical Trial ◽  
Surgical Approaches ◽  
Intrabony Defects ◽  
Patient Centered

Clinical and patient‐centered outcomes using two types of subepithelial connective tissue grafts: A split‐mouth randomized clinical trial

2020 ◽  
Author(s):  
Mariana Schutzer Ragghianti Zangrando ◽  
Ricardo Rabelo Eustachio ◽  
Maria Lúcia Rubo Rezende ◽  
Adriana Campos Passanezi Sant'ana ◽  
Carla Andreotti Damante ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Connective Tissue ◽  
Randomized Clinical Trial ◽  
Patient Centered ◽  
Tissue Grafts

Intrabony Defects, Open-Flap Debridement, and Decortication: A Randomized Clinical Trial

2014 ◽  
Vol 85 (1) ◽  
pp. 34-42 ◽  
Author(s):  
Alessandro Crea ◽  
Giorgio Deli ◽  
Cristiano Littarru ◽  
Carlo Lajolo ◽  
Gianluca Vittorini Orgeas ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Intrabony Defects ◽  
Open Flap Debridement

Comparison of Injectable Calcium Phosphate Bone Cement Grafting and Open Flap Debridement in Periodontal Intrabony Defects: A Randomized Clinical Trial

2008 ◽  
Vol 79 (1) ◽  
pp. 25-32 ◽  
Author(s):  
Yoshinori Shirakata ◽  
Takashi Setoguchi ◽  
Miho Machigashira ◽  
Takashi Matsuyama ◽  
Yasushi Furuichi ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Calcium Phosphate ◽  
Bone Cement ◽  
Randomized Clinical Trial ◽  
Intrabony Defects ◽  
Calcium Phosphate Bone Cement ◽  
Open Flap Debridement

scholarly journals Novel Trial Design: CHIEF-HF

2021 ◽  
Vol 14 (3) ◽  
Author(s):  
John A. Spertus ◽  
Mary C. Birmingham ◽  
Javed Butler ◽  
Ildiko Lingvay ◽  
David E. Lanfear ◽  
...  
Keyword(s):  
Heart Failure ◽  
Clinical Trial ◽  
Ejection Fraction ◽  
Randomized Clinical Trial ◽  
Kansas City ◽  
Mobile Technologies ◽  
Patient Centered ◽  
Kansas City Cardiomyopathy Questionnaire ◽  
Diabetes Status ◽  
Patient Reported

Background: The expense of clinical trials mandates new strategies to efficiently generate evidence and test novel therapies. In this context, we designed a decentralized, patient-centered randomized clinical trial leveraging mobile technologies, rather than in-person site visits, to test the efficacy of 12 weeks of canagliflozin for the treatment of heart failure, regardless of ejection fraction or diabetes status, on the reduction of heart failure symptoms. Methods: One thousand nine hundred patients will be enrolled with a medical record-confirmed diagnosis of heart failure, stratified by reduced (≤40%) or preserved (>40%) ejection fraction and randomized 1:1 to 100 mg daily of canagliflozin or matching placebo. The primary outcome will be the 12-week change in the total symptom score of the Kansas City Cardiomyopathy Questionnaire. Secondary outcomes will be daily step count and other scales of the Kansas City Cardiomyopathy Questionnaire. Results: The trial is currently enrolling, even in the era of the coronavirus disease 2019 (COVID-19) pandemic. Conclusions: CHIEF-HF (Canagliflozin: Impact on Health Status, Quality of Life and Functional Status in Heart Failure) is deploying a novel model of conducting a decentralized, patient-centered, randomized clinical trial for a new indication for canagliflozin to improve the symptoms of patients with heart failure. It can model a new method for more cost-effectively testing the efficacy of treatments using mobile technologies with patient-reported outcomes as the primary clinical end point of the trial. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04252287.

Sign in / Sign up

Export Citation Format

Share Document